935877-74-0Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY
-
Paragraph 0134; 0143; 0144, (2020/06/19)
The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Page/Page column 59; 63; 65, (2015/06/25)
This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with ex
2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
-
Page/Page column 79, (2008/06/13)
The present invention is directed to 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
